MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $823,000 Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in AtriCure, Inc. (NASDAQ:ATRC) by 3.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,916 shares of the medical device company’s stock after buying an additional 1,013 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.06% of AtriCure worth $823,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the business. LMR Partners LLP bought a new stake in AtriCure during the 4th quarter worth approximately $499,000. Graham Capital Management L.P. acquired a new position in AtriCure during the 4th quarter worth about $649,000. Focus Partners Wealth acquired a new position in AtriCure during the 4th quarter worth about $498,000. G2 Investment Partners Management LLC grew its position in shares of AtriCure by 7.2% in the 4th quarter. G2 Investment Partners Management LLC now owns 29,691 shares of the medical device company’s stock valued at $907,000 after buying an additional 1,999 shares during the last quarter. Finally, Centiva Capital LP acquired a new stake in shares of AtriCure in the fourth quarter valued at about $510,000. Institutional investors own 99.11% of the company’s stock.

Insiders Place Their Bets

In related news, Director Karen Prange sold 6,100 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the transaction, the director now directly owns 17,828 shares of the company’s stock, valued at $679,603.36. This trade represents a 25.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 3.50% of the company’s stock.

AtriCure Stock Performance

ATRC opened at $32.71 on Tuesday. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $43.11. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -34.43 and a beta of 1.57. The company’s fifty day moving average price is $32.34 and its two-hundred day moving average price is $34.75. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.11. The business had revenue of $123.62 million for the quarter, compared to analysts’ expectations of $122.92 million. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The firm’s revenue for the quarter was up 13.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.28) EPS. On average, analysts expect that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ATRC has been the topic of several analyst reports. BTIG Research reiterated a “buy” rating on shares of AtriCure in a report on Thursday, March 27th. Needham & Company LLC reduced their price objective on shares of AtriCure from $51.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. Canaccord Genuity Group lowered their target price on shares of AtriCure from $66.00 to $52.00 and set a “buy” rating for the company in a research note on Friday, March 28th. UBS Group cut their price target on shares of AtriCure from $60.00 to $58.00 and set a “buy” rating on the stock in a research report on Wednesday, April 30th. Finally, Stifel Nicolaus lifted their price objective on AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $50.67.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.